2014
Posttreatment Effects of Topiramate Treatment for Heavy Drinking
Kranzler HR, Wetherill R, Feinn R, Pond T, Gelernter J, Covault J. Posttreatment Effects of Topiramate Treatment for Heavy Drinking. Alcohol Clinical And Experimental Research 2014, 38: 3017-3023. PMID: 25581656, PMCID: PMC4293099, DOI: 10.1111/acer.12578.Peer-Reviewed Original ResearchConceptsPercent days abstinentHeavy drinking daysTopiramate treatmentHeavy drinkingDrinking daysHeavy drinkersAllele homozygotesPlacebo-controlled trialEffects of topiramateEnd of treatmentPersistent therapeutic effectKainate receptor subunitsHigher percent days abstinentTherapeutic effectTreatment goalsAlcohol-related problemsAllele carriersDays abstinentAbstinent daysPosttreatment effectsReceptor subunitsReduced drinkingSingle nucleotide polymorphismsStatistical significanceComplete data
2004
Allelic and haplotypic association of GABRA2 with alcohol dependence
Covault J, Gelernter J, Hesselbrock V, Nellissery M, Kranzler HR. Allelic and haplotypic association of GABRA2 with alcohol dependence. American Journal Of Medical Genetics Part B Neuropsychiatric Genetics 2004, 129B: 104-109. PMID: 15274050, DOI: 10.1002/ajmg.b.30091.Peer-Reviewed Original ResearchConceptsAlcohol-dependent subjectsAlcohol dependenceSingle nucleotide polymorphismsMajor depressive episodeGABAA receptor subunitsSubstance use disordersHaplotypic associationsEvidence of associationSerious morbidityOpioid dependenceAlpha 2 subunitDepressive episodePrevalent disorderUse disordersEuropean-American subjectsNeurotransmitter receptorsControl groupDrug dependenceReceptor subunitsCommon haplotypeGABRA2 geneBehavioral effectsImportant mediatorAssociationSubjects